Revenue decline driven by lower Canadian medical cannabis sales and consumer business wind down, offset by international growth
Result Drivers
Canadian reimbursement cuts - Co said lower Canadian medical cannabis revenue was mainly due to federal reimbursement rate reductions effective April 1, 2026
International growth - Co said international medical cannabis revenue rose 17% yr/yr, mainly due to higher sales in Germany driven by increased patient demand
Consumer business wind down - Co attributed lower consumer cannabis revenue to its strategic shift away from the consumer business
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Aurora Cannabis Inc is C$5.00, about 27.9% above its August 4 closing price of C$3.91
ACB•
